These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2110842)

  • 1. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma.
    Henriksson P; Blombäck M; Eriksson A; Stege R; Carlström K
    Br J Urol; 1990 Mar; 65(3):282-5. PubMed ID: 2110842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer.
    Henriksson P; Blombäck M; Bratt G; Edhag O; Eriksson A; Vesterqvist O
    Med Oncol Tumor Pharmacother; 1989; 6(3):219-25. PubMed ID: 2515399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of parenteral estrogen versus orchiectomy on blood coagulation and fibrinolysis in prostatic cancer patients.
    Aro J; Haapiainen R; Rasi V; Rannikko S; Alfthan O
    Eur Urol; 1990; 17(2):161-5. PubMed ID: 2178941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O
    Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
    Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO
    Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ethinyl oestradiol/polyoestradiol phosphate and estramustine phosphate on some proteins related to haemostasis in prostatic carcinoma patients.
    Damber JE; Daehlin L; Tomic R; Nilsson TK
    Int Urol Nephrol; 1991; 23(3):251-6. PubMed ID: 1889971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy.
    Henriksson P; Blombäck M; Bratt G; Edhag O; Eriksson A
    Thromb Res; 1986 Dec; 44(6):783-91. PubMed ID: 3798420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.
    Carlström K; Stege R
    Urol Int; 1990; 45(3):160-3. PubMed ID: 2161578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deteriorated arterial supply to the lower limb during oral oestrogen therapy of patients with prostatic carcinoma.
    Henriksson P; Linde B
    Urol Int; 1994; 53(2):74-8. PubMed ID: 7801420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Hedlund PO; Henriksson P
    Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism.
    Ockrim JL; Lalani el-N; Kakkar AK; Abel PD
    J Urol; 2005 Aug; 174(2):527-33; discussion 532-3. PubMed ID: 16006886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer.
    Henriksson P; Linde B; Edhag O
    Eur Heart J; 1987 Jul; 8(7):779-84. PubMed ID: 3653128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single drug polyestradiol phosphate therapy in prostatic cancer.
    Stege R; Carlström K; Collste L; Eriksson A; Henriksson P; Pousette A
    Am J Clin Oncol; 1988; 11 Suppl 2():S101-3. PubMed ID: 3242384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic model of testosterone suppression after intramuscular depot estrogen therapy in prostate cancer.
    Johansson CJ; Gunnarsson PO
    Prostate; 2000 Jun; 44(1):26-30. PubMed ID: 10861754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intramuscular depot estrogens (Estradurin) in treatment of patients with prostate carcinoma. Historical aspects, mechanism of action, results and current clinical status].
    Stege R; Carlström K; Hedlund PO; Pousette A; von Schoultz B; Henriksson P
    Urologe A; 1995 Sep; 34(5):398-403. PubMed ID: 7483157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.